Cure My Disease

Don't miss your cure!

 Log in / Sign up

New prostate cancer pill could rival current standard treatment

NCT ID NCT07241416

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial compares a new oral drug, rezvilutamide, against the current standard enzalutamide, both combined with hormone therapy, in 206 men with low-volume metastatic prostate cancer that still responds to hormones. The main goal is to see if rezvilutamide can lower PSA levels more effectively within six months. Participants must have good overall health and adequate organ function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Rezvilutamide (a drug taken by mouth to block androgen receptors, similar to enzalutamide)
What this could lead to
If successful, this could offer a new treatment option for men with low-volume metastatic prostate cancer that has not yet become resistant to hormone therapy.
What could go wrong
This is a Phase 3 trial, but it is still recruiting and results are not yet available. The new drug may not prove better or safer than the existing standard, enzalutamide.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Medical Center of the Chinese People's Liberation Army (PLA) General Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100853, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.